| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H19Cl2N3O6S3 |
| Molecular Weight | 576.493 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(S1)S(=O)(=O)NC2=CC=C(Cl)C=C2C(=O)NC3=CC=C(C=C3)S(=O)(=O)N4CCOCC4
InChI
InChIKey=PQHLRGARXNPFCF-UHFFFAOYSA-N
InChI=1S/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27)
Ataciguat is a novel anthranilic acid derivative that belongs to a new structural class of sGC activators which are capable of activating the oxidized form of sGC. Ataciguat, a nitric oxide-independent soluble guanylate cyclase activator, is being developed by Sanofi (previously sanofi-aventis), in collaboration with Mayo Clinic and National Center for Advancing Translational Sciences. Ataciguat is in phase II clinical trials for the treatment of aortic valve stenosis. It had been used to treat neuropathic pain and peripheral arterial disease, but this research has been discontinued.
Originator
Approval Year
AUC
Sourcing
PubMed
Patents
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
